advertisement
Abstract #6440 Published in IGR 3-2
Effect of topical dorzolamide hydrochloride on neovascular glaucoma
Hagiwara Y; Kimura Y; Miura F; Ito K; Otsubo A; Hagiwara N; Uehara H; Koike T; Kishi SJapanese Journal of Clinical Ophthalmology 2001; 55: 1171-1174
The authors evaluated the effect of topical dorzolamide hydrochloride on neovascular glaucoma in 54 eyes of 43 cases. The series comprised diabetic retinopathy (49 eyes), stenosis or constriction of carotid artery (three eyes), and central retinal artery occlusion (two eyes). All the eyes had received panphotocoagulation. After treatment for three months or longer, the control of intraocular pressure (IOP) was fair to good in 39 eyes (72%). The other 15 eyes additionally required retinal photocoagulation, transscleral ciliary photocoagulation or filtration surgery. In 30 eyes treated by topical instillation alone, the average IOP significantly decreased from the pretreatment level after one, three, and six months. In nine eyes receiving peroral carbonic anhydrase inhibitor, it could be discontinued in four eyes and reduced in dosage in two. These findings show that topical dorzolamide is effective for neovascular glaucoma and that it may induce reduction or discontinuation of carbonic anhydrase inhibitor. LA: Japanese
Dr Y. Hagiwara, Department of Ophthalmology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi-shi, Gunma-ken 371-8511, Japan
Classification:
9.4.5.1 Neovascular glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
